Predictors of E-cigarette and Cigarette Use Trajectory Classes from Early Adolescence to Emerging Adulthood Across Four Years (2013-2017) of the PATH Study.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
09 02 2023
Historique:
received: 27 04 2021
revised: 10 02 2022
accepted: 09 05 2022
pubmed: 14 5 2022
medline: 14 2 2023
entrez: 13 5 2022
Statut: ppublish

Résumé

This study examines predictors of trajectories of cigarette and e-cigarette use among a cohort of US adolescents transitioning into young adulthood. Comparing trajectories of each tobacco product is important to determine if different intervention targets are needed to prevent progression to daily use. Latent trajectory class analyses identified cigarette and e-cigarette use (never, ever excluding past 12-month, past 12-month (excluding past 30-day (P30D)), P30D 1-5 days, P30D 6+ days) trajectory classes, separately, among US youth (12-17; N = 10,086) using the first 4 waves (2013-2017) of data from the nationally representative PATH Study. Weighted descriptive analyses described the class characteristics. Weighted multinomial logistic regression analyses examined demographic, psychosocial, and behavioral predictors of class membership. Younger adolescents 12-15 years had lower tobacco use compared to 16-17 year olds and less stable classes. In the 16-17 year group, there were five unique trajectories of cigarette smoking, including a Persistent High Frequency class. Four e-cigarette use trajectories were identified; but not a persistent use class. Shared predictors of class membership for cigarettes and e-cigarettes included mental health problems, other tobacco use, marijuana use, and poorer academic achievement. Male sex and household tobacco use were unique e-cigarette trajectory class predictors. There was no evidence that initiation with e-cigarettes as the first product tried was associated with cigarette progression (nor cigarettes as first product and e-cigarette progression). Interventions should focus on well-established risk factors such as mental health and other substance use to prevent progression of use for both tobacco products. Using nationally representative data and definitions of use that take into account frequency and recency of use, longitudinal 4-year trajectories of e-cigarette and cigarette use among US adolescents transitioning into young adulthood were identified. Results among 16-17-year olds revealed a class of persistent high frequency cigarette smoking that was not identified for e-cigarette use. Cigarette use progression was not associated with e-cigarettes as the first product tried. Risk factors for progression of use of both products included mental health and other substance use, which are important prevention targets for both tobacco products.

Identifiants

pubmed: 35554569
pii: 6584494
doi: 10.1093/ntr/ntac119
pmc: PMC9910140
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

421-429

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.

Références

MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1881-1888
pubmed: 33332300
JAMA Netw Open. 2020 Nov 2;3(11):e2015893
pubmed: 33231634
JAMA. 2015 Aug 18;314(7):700-7
pubmed: 26284721
PLoS One. 2017 Feb 9;12(2):e0171808
pubmed: 28182748
Addict Behav. 2018 Jan;76:208-217
pubmed: 28846942
Int J Environ Res Public Health. 2019 Jun 17;16(12):
pubmed: 31212888
Pediatrics. 2018 Sep;142(3):
pubmed: 30177516
Int J Environ Res Public Health. 2021 Feb 10;18(4):
pubmed: 33578770
Health Psychol. 2000 May;19(3):223-31
pubmed: 10868766
J Adolesc Health. 2019 Jun;64(6):770-775
pubmed: 31122507
MMWR Morb Mortal Wkly Rep. 2018 Nov 09;67(44):1225-1232
pubmed: 30408019
Nicotine Tob Res. 2008 Aug;10(8):1283-91
pubmed: 18686175
Tob Control. 2020 May;29(Suppl 3):s147-s154
pubmed: 32321848
Addiction. 2020 Apr;115(4):740-747
pubmed: 31618491
Drug Alcohol Depend. 2019 Aug 1;201:85-93
pubmed: 31200279
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
Psychol Addict Behav. 2016 Dec;30(8):876-886
pubmed: 27669093
Am J Public Health. 2016 Apr;106(4):672-8
pubmed: 26794178
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):597-603
pubmed: 28617771
Addict Behav. 2021 Jan;112:106593
pubmed: 32927247
Addict Behav Rep. 2020 Sep 09;12:100303
pubmed: 33364312
MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):157-164
pubmed: 30763302
Tob Control. 2019 Nov;28(6):663-668
pubmed: 30297373
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
BMJ. 2019 Jun 20;365:l2219
pubmed: 31221636
Drug Alcohol Depend. 2016 Jun 01;163:261-4
pubmed: 27141841
Drug Alcohol Depend. 2018 Jul 1;188:281-287
pubmed: 29807215
Pediatrics. 2016 Jul;138(1):
pubmed: 27296866
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1310-1312
pubmed: 32941408
Am J Health Promot. 2018 Jun;32(5):1214-1220
pubmed: 29214809
JAMA Pediatr. 2015 Nov;169(11):1018-23
pubmed: 26348249
J Natl Cancer Inst. 2019 Oct 1;111(10):1088-1096
pubmed: 30689915
MMWR Surveill Summ. 2019 Nov 06;68(12):1-22
pubmed: 31805035
Tob Control. 2020 May;29(Suppl 3):s178-s190
pubmed: 32321852
JAMA Pediatr. 2018 Feb 1;172(2):181-187
pubmed: 29297010
Drug Alcohol Depend. 2017 Aug 1;177:77-83
pubmed: 28578225
Health Psychol. 2008 Nov;27(6):811-8
pubmed: 19025277
Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S31-S38
pubmed: 30125023
J Adolesc Health. 2017 Jun;60(6):660-666
pubmed: 28242187

Auteurs

Cassandra A Stanton (CA)

Behavioral Health and Health Policy Practice, Westat Inc, Rockville, MD, USA.
Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.

Zhiqun Tang (Z)

Behavioral Health and Health Policy Practice, Westat Inc, Rockville, MD, USA.

Eva Sharma (E)

Behavioral Health and Health Policy Practice, Westat Inc, Rockville, MD, USA.

Elizabeth Seaman (E)

Behavioral Health and Health Policy Practice, Westat Inc, Rockville, MD, USA.

Lisa D Gardner (LD)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Marushka L Silveira (ML)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Kelly Government Solutions, Rockville, MD, USA.

Dorothy Hatsukami (D)

Masonic Cancer Center, Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA.

Hannah R Day (HR)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

K Michael Cummings (KM)

Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.

Maciej L Goniewicz (ML)

Department of Health Behavior, Division of Cancer Prevention & Population Sciences, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Jean Limpert (J)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Colm Everard (C)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Kelly Government Solutions, Rockville, MD, USA.

Maansi Bansal-Travers (M)

Department of Health Behavior, Division of Cancer Prevention & Population Sciences, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Bridget Ambrose (B)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Heather L Kimmel (HL)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.

Nicolette Borek (N)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Wilson M Compton (WM)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.

Andrew J Hyland (AJ)

Department of Health Behavior, Division of Cancer Prevention & Population Sciences, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Jennifer L Pearson (JL)

School of Community Health Sciences, University of Nevada, Reno, Reno, NV, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH